tazarotene has been researched along with Pain in 8 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background: Tazarotene has been extensively studied in clinical trials and is widely used to treat acne vulgaris (acne)." | 9.30 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris ( Green, LJ; Guenin, E; Harris, S; Kircik, LH; Martin, G; Pillai, R; Tanghetti, EA, 2019) |
| "Background: As current tazarotene formulations indicated for acne (0." | 7.96 | Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis. ( Guenin, E; Harris, S; Lain, E; Loncaric, A; Pillai, R; Tanghetti, EA; Werschler, WP, 2020) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 6.90 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials ( Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019) |
| "Background: Tazarotene has been extensively studied in clinical trials and is widely used to treat acne vulgaris (acne)." | 5.30 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris ( Green, LJ; Guenin, E; Harris, S; Kircik, LH; Martin, G; Pillai, R; Tanghetti, EA, 2019) |
| "Background: As current tazarotene formulations indicated for acne (0." | 3.96 | Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis. ( Guenin, E; Harris, S; Lain, E; Loncaric, A; Pillai, R; Tanghetti, EA; Werschler, WP, 2020) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 2.90 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials ( Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019) |
| " Our purpose is to compare the rates of adverse events associated with different topical psoriasis treatments." | 2.42 | A systematic review of adverse effects associated with topical treatments for psoriasis. ( Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lebwohl, MG | 1 |
| Sugarman, JL | 2 |
| Stein Gold, L | 3 |
| Lin, T | 3 |
| Israel, R | 2 |
| Elewski, B | 1 |
| Draelos, Z | 1 |
| Jacobson, A | 1 |
| Tanghetti, EA | 3 |
| Werschler, WP | 1 |
| Lain, E | 1 |
| Guenin, E | 2 |
| Harris, S | 2 |
| Loncaric, A | 1 |
| Pillai, R | 3 |
| He, C | 1 |
| Jin, H | 1 |
| Liu, X | 1 |
| Hu, F | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| He, Y | 1 |
| Yang, X | 1 |
| Chen, H | 1 |
| Wang, X | 1 |
| Ji, C | 1 |
| Lv, C | 1 |
| Miao, G | 1 |
| Li, X | 2 |
| Diao, Q | 1 |
| Li, L | 1 |
| Li, Y | 1 |
| Wang, R | 1 |
| Zhou, X | 1 |
| Xia, X | 1 |
| Yan, M | 1 |
| Song, J | 1 |
| Zhang, R | 1 |
| Geng, L | 1 |
| Zheng, M | 1 |
| Lu, Q | 1 |
| Lu, T | 1 |
| Shi, Y | 1 |
| Jing, H | 1 |
| Zhang, X | 1 |
| Shi, J | 1 |
| Xia, J | 1 |
| Gao, Y | 1 |
| Wang, Y | 1 |
| Weiss, J | 1 |
| Bagel, J | 1 |
| Yamauchi, PS | 1 |
| Martin, G | 2 |
| Kircik, LH | 1 |
| Green, LJ | 1 |
| Bruner, CR | 1 |
| Feldman, SR | 1 |
| Ventrapragada, M | 1 |
| Fleischer, AB | 1 |
| Waller, JM | 1 |
| Wu, JJ | 1 |
| Murase, JE | 1 |
| Dyson, SW | 1 |
| Kelly, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Excimer Laser Combined With Either Topical Tazarotene or Topical Betamethasone Valerate Versus Excimer Laser Alone in Treatment of Localized Chronic Plaque Psoriasis; Clinical and Dermoscopic Study[NCT05555797] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-10-30 | Not yet recruiting | ||
| Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet[NCT04720105] | Phase 4 | 22 participants (Actual) | Interventional | 2020-11-19 | Completed | ||
| Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis[NCT01205880] | Phase 4 | 12 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient-reported outcomes evaluated by Dermatology Quality of Life Index (DLQI). DLQi is a 10-item questionnaire, each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 6.24 | 4.94 |
Treatment satisfaction evaluated by a Numerical Rating Scale (NRS). Full scale from 0 to 10, higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 1.35 | 1.29 |
Number of participants achieving Palmoplantar Physician Global Assessment (ppPGA) of 0 (clear) or 1 (almost clear/minimal) after 24 weeks of treatment. The ppPGA is based on the Investigators Global Assessment (IGA) modified version 11, specifically applied to the hands and/or feet: 0 (clear), 1 (almost clear/minimal), 2 (mild), 3 (moderate), 4 (marked/moderate-to-severe), 5 (severe) (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 3.47 | 2.24 |
2 reviews available for tazarotene and Pain
| Article | Year |
|---|---|
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations; | 2018 |
A systematic review of adverse effects associated with topical treatments for psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Dermatologic Agen | 2003 |
3 trials available for tazarotene and Pain
3 other studies available for tazarotene and Pain
| Article | Year |
|---|---|
Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
Topics: Acne Vulgaris; Adolescent; Adult; Aged; Child; Clinical Trials, Phase III as Topic; Double-Blind Met | 2020 |
Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone; Dermatologic Agents; Drug | 2021 |
Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Aged; Chronic Disease; Dermatologic Agents; Diagnosis, Differential; Female; Humans; | 2007 |